Morgan Stanley Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

In a report released yesterday, David Bailey from Morgan Stanley maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. The company’s shares closed today at A$37.06.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Bailey is a 4-star analyst with an average return of 10.2% and a 46.15% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, Resmed, and CSL.

Currently, the analyst consensus on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is a Strong Buy with an average price target of A$48.11, representing a 29.82% upside. In a report released yesterday, Canaccord Genuity also assigned a Buy rating to the stock with a A$46.50 price target.

Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$1.45 billion and a net profit of A$399.08 million. In comparison, last year the company earned a revenue of A$1.28 billion and had a net profit of A$344.62 million